Prelude Therapeutics (PRLD) Revenue (2024 - 2026)

Prelude Therapeutics (PRLD) has 3 years of Revenue data on file, last reported at $4.6 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue changed N/A year-over-year to $4.6 million; the trailing twelve-month figure through Mar 2026 stood at $16.7 million (changed N/A YoY), and the FY2025 full-year result was $12.1 million, up 73.43% from the prior year.
• Revenue eased to $4.6 million in Q1 2026, from $5.6 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $6.5 million in Q3 2025 to a low of $3.0 million in Q3 2024.
• A 3-year average of $4.7 million and a median of $4.6 million in 2026 frame the typical range for Revenue.
• Peak annual rise in Revenue reached 116.67% in 2025, while the deepest fall reached 41.0% in 2025.
• Tracing PRLD's Revenue over 3 years: stood at $4.0 million in 2024, then jumped by 41.0% to $5.6 million in 2025, then decreased by 18.79% to $4.6 million in 2026.
• Business Quant data shows PRLD's Revenue at $4.6 million in Q1 2026, $5.6 million in Q4 2025, and $6.5 million in Q3 2025.